Ahn M. New agents in the management of small cell lung cancer. Presented at: the American Society of Clinical Oncology (ASCO®) Meeting; June 4-8, 2021; Virtual. Presentation.
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342-2350.
Ardizzoni A, Tiseo M, Boni L. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. Eur J Cancer. 2014;50:2211-2218.
Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995;87:183-190.
Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476-484.
Baize N, Monnet I, Greillier L, et al; Groupe Français de Pneumo-Cancérologie 01–13 Investigators. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2020;21:1224-1233.
Byers LA. Presented at: the American Society of Clinical Oncology (ASCO®) Meeting; May 29-31, 2020; Virtual.
Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15:618-627.
Clinicaltrials.gov. A study of BMS-986012 in Combination with carboplatin, etoposide, and nivolumab as first-line therapy in extensive-stage small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT04702880. Updated January 11, 2021. Accessed June 14, 2021.
ClinicalTrials.gov. SWOG S1827 (MAVERICK) Testing whether the use of brain scans alone instead of brain scans plus preventive brain radiation affects lifespan in patients with small cell lung cancer. Updated July 12, 2021. Accessed July 26, 2021. https://clinicaltrials.gov/ct2/show/NCT04155034
ClinicalTrials.gov. Testing the addition of radiation therapy to the usual immune therapy treatment (atezolizumab) for extensive stage small cell lung cancer, the RAPTOR trial. Updated July 21, 2021. Accessed July 26, 2021. https://clinicaltrials.gov/ct2/show/NCT04402788
Daly ME, Monjazeb AM, Kelly K. Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer. J Thorac Oncol. 2015;10:1685-1693.
Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687-695.
Einsele H, Borghaei H, Orlowski RZ, et al. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126:3192-3201.
Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, et al. ATLANTIS: a phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncol. 2019;15:231-239.
Genentech USA, Inc. Tecentriq clinical data efficacy. 2021. Accessed July 23, 2021. https://www.tecentriq-hcp.com/sclc/clinical-data-efficacy/study-efficacy.html
Gjyshi O, Ludmir EB, Pezzi TA, et al. Evolving practice patterns in the use of prophylactic cranial irradiation for extensive-stage small cell lung cancer. JAMA Netw Open. 2019;2:e199135.
Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016;17:1147-1157.
Herbreteau G, Langlais A, Greillier L, et al. Circulating tumor DNA as a prognostic determinant in small cell lung cancer patients receiving atezolizumab. J Clin Med. 2020;9:3861.
Higgins KA, Curran WJ Jr, Liu SV, et al. Patterns of disease progression after carboplatin/etoposide + atezolizumab in extensive-stage small-cell lung cancer (ES-SCLC). Int J Radiat Oncol Biol Phys. 2020;108:1398.
Hipp S, Voynov V, Drobits-Handl B, et al. A bispecific DLL3/CD3 IgG-like T-cell engaging antibody induces antitumor responses in small cell lung cancer. Clin Cancer Res. 2020;26:5258-5268.
Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229
Kaur P, Asea A. Radiation-induced effects and the immune system in cancer. Front Oncol. 2012;2:191.
Leal JF, Martínez-Díez M, García-Hernández V, et al. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol. 2010;161:1099-1110.
Leal TA, Wang Y, Dowlati A, et al. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. Presented at: the American Society of Clinical Oncology (ASCO®) Meeting; May 29-31, 2020; Virtual. Abstract 9000.
Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619-630.
National Comprehensive Cancer Network (NCCN). Small-cell lung cancer (Version 3.2021). 2021. Accessed July 26, 2021. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
Olmedo Garcia ME, Forster M, Calvo E, et al. Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC). Ann Oncol. 2017;28(suppl 5): Abstract 1529PD.
Owonikoko TK, Champiat S, Johnson ML, et al. Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). J Clin Oncol. 2021;39(suppl 15): Abstract 8510.
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929-1939.
Paz-Ares LG, Dvorkin M, Chen Y, et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study Presented at: the American Society of Clinical Oncology (ASCO®) Meeting; May 29-31, 2020; Virtual. Abstract 9002.
Paz-Ares LG, Dvorkin M, Chen Y, et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study. J Clin Oncol. 2020;38:15_suppl, 9002-9002.
Pujol JL, Greillier L, Audigier-Valette C, et al. A randomized non-comparative phase ii study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 Trial. J Thorac Oncol. 2019;14:903-913.
Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol. 2020;15:426-435.
Reck M, Liu SV, Mansfield AS, et al. IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). Presented at: the European Society for Medical Oncology (ESMO) Congress; September 27-October 1, 2019; Barcelona, Spain. Abstract 2374. ESMO 2019. Abstract 2374.
Reck M, Vicente D, Ciuleanu T, et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331. Presented at ESMO Immuno-Oncology Congress 2018; December 13-16, 2018; Geneva, Switzerland. Abstract LBA5.
Reinmuth N, Garassino MC, Trukhin D, et al. P48.03 First-line durvalumab plus platinum-etoposide in ES-SCLC: exploratory analyses based on extent of disease in CASPIAN. J Thorac Oncol. 2021;16(3):S500.
Rudin CM, Awad MM, Navarro A, et al. KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC). Presented at: the American Society of Clinical Oncology (ASCO®) Meeting; May 29-31, 2020; Virtual. Abstract 9001.
Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020,38:2369-79.
Santamaría Nuñez G, Robles CM, Giraudon C, et al. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther. 2016;15:2399-2412.
Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664-672.
Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36-42. Erratum in: Lancet. 2015;385:28.
Stieglmaier J, Benjamin J, Nagorsen D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin Biol Ther. 2015;15:1093-1099.
Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663-671.
The ASCO Post Staff. FDA grants accelerated approval to lurbinectedin for metastatic SCLC. ASCO Post. July 12, 2020. Accessed July 26, 2021. https://ascopost.com/issues/july-10-2020/fda-grants-accelerated-approval-to-lurbinectedin-for-metastatic-sclc/
Topotecan Injection [prescribing information]. Teva Pharmaceuticals USA. Approved 1996. Revised February 2014.
Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial [published correction appears in Lancet Oncol. 2020;21(12):e553]. Lancet Oncol. 2020;21:645-654.
Trigo Perez JM, Leary A, Besse B, et al. Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study. J Clin Oncol. 2018;36(suppl): Abstract 8570.
Weiss J, Goldschmidt J, Andric Z, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer. 2021;S1525-7304(21)00064-4.
Welsh JW, Heymach JV, Chen D, et al. Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer. J Thorac Oncol. 2020;15:266-273.
Zepzelca (lurbinectedin) [prescribing information]. Jazz Pharmaceuticals, Inc; Pharma Mar, S. A. Approved 2020. Revised June 2020.

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

All of the relevant financial relationships listed for these individuals have been mitigated.

Faculty

Kristin Higgins, MD

Associate Professor
Department of Radiation Oncology
Emory University School of Medicine
Winship Cancer Institute
Atlanta, Georgia

The opinions expressed are those of Dr Higgins and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Higgins’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Disclosures

Disclosure: Kristin Higgins, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca
Received grants for clinical research from: Reflexion Medical

Taofeek Owonikoko, MD, PhD

Chief, Division of Hematology/Oncology
Associate Director for Translational Research and Co-Leader Cancer Therapeutics Program
UPMC Hillman Cancer Center
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Disclosures

Disclosure: Taofeek Owonikoko, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Bristol Myers Squibb; EMD Serono; Ipsen; Jazz Pharmaceuticals; Merck; Roche; Takeda
Owns stock, stock options, or bonds from: Cambium Oncology

Ticiana Leal, MD

Associate Professor of Medicine
Thoracic Oncology Program Leader
Division of Hematology/Oncology
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Disclosures

Disclosure: Ticiana Leal, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Bayer; Genentech; Janssen; Jazz Pharmaceuticals; Blueprint; Boehringer Ingelheim; EMD Serono; Genentech; Lilly; Mirati

Editor

Megan Cannon, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Megan Cannon, PhD, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

Perspectives in Lung Cancer 2021: Management of SCLC

Authors: Kristin Higgins, MD; Taofeek Owonikoko, MD, PhD; Ticiana Leal, MD
CME / ABIM MOC / CE Released: 9/22/2021
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 9/22/2022

Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, pathologists, radiologists, surgeons, primary care physicians, critical care specialists, internal medicine specialists, emergency medicine physicians, nurses/nurse practitioners, physician assistants, and pharmacists involved in the care of patients with or at risk for lung cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or malignant pleural mesothelioma (MPM).

The goal of this activity is to improve clinicians’ understanding of the therapeutic management of patients with SCLC.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data evaluating regimens used to treat patients with SCLC
- Role of radiation therapy in the management of patients with SCLC
Have greater competence related to
- Tailoring therapy across first-line and second-line settings for patients with SCLC
Demonstrate greater confidence in their ability to
- Understand the clinical implications of the available evidence for therapies in the treatment paradigm of SCLC

Disclosures

All of the relevant financial relationships listed for these individuals have been mitigated.

Faculty

Kristin Higgins, MD

Associate Professor
Department of Radiation Oncology
Emory University School of Medicine
Winship Cancer Institute
Atlanta, Georgia

The opinions expressed are those of Dr Higgins and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Higgins’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Disclosures

Disclosure: Kristin Higgins, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca
Received grants for clinical research from: Reflexion Medical

Taofeek Owonikoko, MD, PhD

Chief, Division of Hematology/Oncology
Associate Director for Translational Research and Co-Leader Cancer Therapeutics Program
UPMC Hillman Cancer Center
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Disclosures

Disclosure: Taofeek Owonikoko, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Bristol Myers Squibb; EMD Serono; Ipsen; Jazz Pharmaceuticals; Merck; Roche; Takeda
Owns stock, stock options, or bonds from: Cambium Oncology

Ticiana Leal, MD

Associate Professor of Medicine
Thoracic Oncology Program Leader
Division of Hematology/Oncology
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Disclosures

Disclosure: Ticiana Leal, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Bayer; Genentech; Janssen; Jazz Pharmaceuticals; Blueprint; Boehringer Ingelheim; EMD Serono; Genentech; Lilly; Mirati

Editor

Megan Cannon, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Megan Cannon, PhD, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education

CME / ABIM MOC / CE

Perspectives in Lung Cancer 2021: Management of SCLC

Authors: Kristin Higgins, MD; Taofeek Owonikoko, MD, PhD; Ticiana Leal, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 9/22/2021

Valid for credit through: 9/22/2022

processing....

BM = brain metastases
BP = blood pressure
CDK = cyclin-dependent kinase
CNS = central nervous system
CR = complete response
CT = computed tomography
CTFI = chemotherapy-free interval
ECOG = Eastern Cooperative Oncology Group
ES = extensive-stage
HA = hippocampus avoidance
IMRT = intensity-modulated radiation therapy
IO = immuno-oncology
ITT = intention-to treat
MPM = malignant pleural mesothelioma
MRI = magnetic resonance imaging
NCCN = National Comprehensive Cancer Network
NSCLC = non-small cell lung cancer
ORR = overall response rate
OS = overall survival
PCI = prophylactic cranial irradiation
PD = progressive disease
PD-L1 = programmed death-ligand 1
PET = positron emission tomography
PFS = progression-free survival
PR = partial response
PS = performance status
RCT = randomized controlled trial
RECIST = Response Evaluation Criteria in Solid Tumors
RML = right middle lobe
RR = respiratory rate
RT = radiotherapy
SCLC = small-cell lung cancer
SD = stable disease
SIADH = syndrome of inappropriate antidiuretic hormone secretion
TFI = treatment-free interval
TRT = thoracic radiotherapy
WBRT = whole brain radiotherapy